Introduction:
Novo Nordisk, a prominent pharmaceutical company, will discontinue Levemir, a long-acting insulin vital for individuals managing diabetes. This decision marks the conclusion of production for one of Novo Nordisk’s leading products.
Levemir’s Discontinuation Timeline:
- When: Levemir’s availability will diminish gradually.
- Levemir FlexPen: Supply disruption is anticipated from mid-January 2024 till its discontinuation on April 1.
- Levemir in Vials: Ceasing supply after Dec. 31, 2024.
- Supply Chain Issues: Novo Nordisk alerts about impending Levemir shortages due to supply chain challenges.
Reasons for Discontinue Levemir:
- Global Constraints: Global manufacturing limitations impact production.
- Formulary Losses: Impact on patient access due to formulary changes.
- Alternative Options: Availability of alternative treatment choices influencing the decision.
Please fill out the form if you or a friend would like more information on CGMs.
Levemir vs. Tresiba: A Comparison:
- Levemir: Introduced in 2005, a long-acting insulin starting effect within 1-2 hours, active for up to 24 hours, with some patients needing twice-daily dosing.
- Tresiba: Novo Nordisk’s newer product (approved in 2015), offering a 42-hour duration and injected once daily, allowing flexible dosing schedules.
Must Read CGMs in noncritical care hospitals optimizes glycemic control
Market Shift Towards Tresiba:
- Sales Performance: Tresiba surpasses Levemir in sales, attributed to its less frequent dosing and lower instances of severe hypoglycemia.
Impact of Discontinuation:
- Market Evolution: Newer, more effective basal insulins, like Tresiba, enter the market, rendering older-generation insulins, such as Levemir, obsolete.
- Consumer Impact: Levemir’s discontinuation, especially amid significant price cuts, could restrict access to essential medications for many diabetes patients.
Read Guide about Wegovy Dosage Guide: The Best Way For Weight Loss
Expert Insights:
Dr. Philip Home speculates production concerns for other drugs might be a driving force behind Levemir’s discontinuation, aiming to allocate manufacturing resources efficiently.
Also, read about Impact of Salt Intake on Type 2 Diabetes Risk
Recommendations for Levemir Users:
- Consultation: Discuss alternative long-acting insulin options with healthcare providers.
- Formulary and Price Cuts: Explore formulary-covered or recently priced-reduced insulin alternatives if currently using Levemir.
